Prolactin (PRL) exists in human serum in several molecular forms that can be identified by gel-filtration chromatography (GFC). The 23-kDa monomer is the predominant form in the general population, but other circulating species include the 50-kDa form (big PRL) and the 150-to 170-kDa macroprolactin (big big PRL) (1, 2 ) . The prevalence of macroprolactin in the general population is currently unknown, but this macromolecular form of PRL has been characterized as a complex of PRL with an IgG antibody (3 ) that has reduced bioactivity in vivo (4 ) and a variable reactivity with commercial immunoassays for PRL (4 -8 ). Macroprolactin is cleared from the blood circulation more slowly than monomeric PRL, leading to an apparent hyperprolactinemia, depending on the immunoassay used for the measurement of PRL. Thus, identification of macroprolactin as a cause of high PRL in a patient sample is important because it can help resolve diagnostic confusion and avoid expensive pituitary imaging studies and inappropriate treatment (5 ). As a result of distribution of serum containing macroprolactin in the United Kingdom National External Quality Assessment Scheme, immunoassays for the measurement of PRL have been subdivided into three classes according to their reactivity with macroprolactin: low-, medium-, and highreading methods (6 ).
Prolactin (PRL) exists in human serum in several molecular forms that can be identified by gel-filtration chromatography (GFC). The 23-kDa monomer is the predominant form in the general population, but other circulating species include the 50-kDa form (big PRL) and the 150-to 170-kDa macroprolactin (big big PRL) (1, 2 ) . The prevalence of macroprolactin in the general population is currently unknown, but this macromolecular form of PRL has been characterized as a complex of PRL with an IgG antibody (3 ) that has reduced bioactivity in vivo (4 ) and a variable reactivity with commercial immunoassays for PRL (4 -8 ) . Macroprolactin is cleared from the blood circulation more slowly than monomeric PRL, leading to an apparent hyperprolactinemia, depending on the immunoassay used for the measurement of PRL. Thus, identification of macroprolactin as a cause of high PRL in a patient sample is important because it can help resolve diagnostic confusion and avoid expensive pituitary imaging studies and inappropriate treatment (5 ) . As a result of distribution of serum containing macroprolactin in the United Kingdom National External Quality Assessment Scheme, immunoassays for the measurement of PRL have been subdivided into three classes according to their reactivity with macroprolactin: low-, medium-, and highreading methods (6 ) .
We used the polyethylene glycol (PEG) precipitation method (4 ) to screen for the presence of macroprolactinemia in a population of 319 samples with increased serum PRL (Ͼ30 g/L) measured by our routine method [electrochemiluminescence immunoassay (Elecsys 2010; Roche)], an immunoassay that reacts strongly with macroprolactin (high-reading method). The presence of macroprolactin was confirmed by GFC on a Sephacryl S-300 column (Pharmacia) as described elsewhere (4 ) . All samples containing macroprolactin, as well as 48 hyperprolactinemic samples containing exclusively monomeric PRL, were additionally assayed for PRL by two other commercially available automated immunoassay systems: a medium-reading method for macroprolactin [chemiluminescent immunoassay (Immulite; Diagnostic Products Corporation)] and a low-reading method [chemiluminescent immunoassay (ACS:180; Bayer)].
PEG precipitation has been validated as a screening method for the presence of macroprolactin only when used with the Wallac Delfia PRL assay (4 ) . In our experiments with PEG precipitation (250 g/L PEG 6000 at room temperature, freshly prepared PEG reagent every 3 months) and the Elecsys PRL assay, we obtained the following results: over a 2-week period, 10 repeated determinations of PRL recovery after PEG precipitation of a sample containing exclusively monomeric PRL and a sample containing 82% macroprolactin gave mean recoveries of 84% (SD, 5%) and 14% (SD, 0.8%), respectively. To validate a cutoff for PEG precipitation with the Elecsys PRL assay, we used a subset of our hyperprolactinemic samples for an initial study. In 30 hyperprolactinemic samples with no evidence of macroprolactin by GFC, the recovery of PRL after PEG precipitation was 53-96%, whereas in 30 samples in which macroprolactin had been identified recovery was 6 -46%. Consequently, when PRL was measured with the Elecsys assay, recovery of Ͻ50% of PRL after PEG precipitation was considered a positive screening result for macroprolactin. The PEG precipitation method, however, could not be used with the two other automated PRL immunoassays because the presence of PEG produced negative interference with the ACS:180 assay (4 ) and positive interference with the Immulite assay (recovery Ͼ100% after PEG precipitation for samples containing monomeric PRL).
In our population of 319 hyperprolactinemic samples, 59 sera (18%) gave a PRL recovery of Ͻ50% after PEG precipitation, and in all of these samples, the presence of macroprolactin was confirmed by GFC. This finding is consistent with the data of other authors reporting a prevalence of 15.4 -26% for macroprolactinemia among hyperprolactinemic samples (4, 7 ) . Fig. 1A compares the Elecsys and the ACS:180 PRL assays. The results obtained with the Elecsys assay were higher than those measured with the ACS:180 assay, and the difference was influenced by the presence of macroprolactin. The results for sera containing only monomeric PRL were, on average, 40% higher with the Elecsys assay (range, 18 -60%) than with the ACS:180 assay, whereas the results for samples containing macroprolactin were on average 78% higher (range, 20 -143%). The samples for which the difference between the Elecsys and the ACS:180 results was Ͼ60% were exclusively macroprolactinemic samples. Of the 59 samples, 17 (29%) containing macroprolactin had a difference between the Elecsys and the ACS:180 results of 20 -59%, which was similar to the difference observed in the monomeric PRL population.
The difference plot for the Elecsys and the Immulite assays ( Fig. 1B) shows that the Elecsys assay gave higher results than the Immulite assay and that the bias was influenced by the presence of macroprolactin. In the Elecsys assay, the sera containing only monomeric PRL gave results that were, on average, 44% higher (range, 14 -79%) than in the Immulite assay, and the macroprolactinemic samples gave results that were 78% higher (range, 46 -130%) on average. All samples presenting a difference Ͼ80% between the Elecsys and the Immulite results were macroprolactinemic samples, and all samples presenting a difference Ͻ45% were samples containing only monomeric PRL. The overlapping of the macroprolactinemic and the monomeric PRL populations was greater than for the Elecsys/ACS:180 comparison because 56% (33 of 59) of the macroprolactinemic samples present a difference of the Elecsys and the Immulite results between 45% and 80%. Fig. 1C compares the medium-reading Immulite method and the low-reading ACS:180 method. Although in some samples the results by the two methods were quite different, there was little overall bias attributable to the presence of macroprolactin. We obtained an average difference of Ϫ5.1% (range, Ϫ51% to 30%) for the monomeric PRL samples and an average difference of 2.4% (range, Ϫ50% to 86%) for the macroprolactin-containing samples.
We confirmed in our study that, in general practice, macroprolactinemia is a common phenomenon in hyperprolactinemic samples. Of the three automated immunoassay systems tested, the Elecsys assay gave higher results than those obtained by the Immulite and the ACS:180 assays, and the bias was influenced considerably by the presence of macroprolactin. Our data confirmed that the reactivity with macroprolactin is dependent on the assay used for the PRL measurement, but we additionally showed that the PRL results obtained for samples containing macroprolactin are also sample dependent. Thus, even if the average difference between results of macroprolactinemic samples measured with the Elecsys and ACS:180 assays (78%) was much higher than the average difference for monomeric PRL samples (40%), we could identify a subpopulation of sera containing macroprolactin that behave like monomeric samples and present only a difference of 20 -59%. Consequently, it is not possible to exclude the presence of macroprolactin by comparison of the results obtained by a high-reading method (Elecsys 2010; Roche) and a low-reading method (ACS:180; Bayer), as has been proposed by some authors (9 ) . In such a comparison, 29% of the macroprolactinemic samples of our population would not have been recognized. The difference plot illustrating the Immulite/ACS:180 comparison (Fig. 1C) shows little overall bias attributable to the presence of macroprolactin, but the considerable range in the differences between the Immulite and the 
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Technical Briefs ACS:180 results obtained for macroprolactinemic samples (range, Ϫ50% to 86%) indicates a highly variable, sampledependent response of the ACS:180 assay to macroprolactin. The great disparity of values observed when comparing results from macroprolactinemic samples measured by the Elecsys or the Immulite assay with the results obtained by a low-reading method such as ACS:180 may reflect variation in the structure of macroprolactin. Macroprolactin is most probably not one unique macromolecule but rather a heterogeneous family of PRL-IgG complexes that react differently depending on the type of immunoassay used for PRL determination.
In conclusion, our study reinforces the point that PRL assays from different manufacturers give highly variable prolactin results for samples containing macroprolactin (4 -8 ) . Our data additionally show that the reactivity of macroprolactin in a PRL immunoassay, be it a low-, medium-, or high-reading method, is not identical for all macroprolactinemic samples. This finding underscores the necessity of a systematic screening strategy for macroprolactin in all samples with increased PRL (4, 5, 10, 11 ) . With the Elecsys PRL assay, PEG precipitation, with a cutoff value of 50%, was an efficient and easy-to-use screening tool for the presence of macroprolactin. Because of the interference of PEG in some commercially available PRL assays, the confirmation of macroprolactinemia may require time-consuming methods, such as centrifugal ultrafiltration (9 ) and GFC.
We thank Michael N. Recently, mutations in several genes that encode for coagulation proteins, such as the factor V (FV):R506Q (G1691A) mutation or the prothrombin (FII):G20210A variant, have been identified as important risk factors for developing a venous thromboembolism (VTE) (1 ) . These mutations contribute to the development of thrombosis in ϳ50% of all patients.
The FV:R506Q (G1691A) mutation currently is considered the most important genetic risk factor for venous thrombosis. Although 5% of the healthy population carry the mutant allele, the prevalence of this mutation in patients with venous thrombosis is ϳ40%. Compared with the wild type, heterozygous carriers of the mutation have an 8-fold higher risk and homozygotes have an 80to 100-fold higher risk of developing a VTE (2 ) . If and how this mutation contributes to arterial thrombosis is still under investigation, although recently Ardissino et al.
(3 ) showed correlations among the factor V mutation, smoking, and myocardial infarction. The FII:G20210A variant, which is associated with increased prothrombin activity and increased plasma prothrombin, has been identified as an independent risk factor for thrombosis (4 ) . Compared with individuals with the wild-type genotype, heterozygous carriers of the mutation have a 2.8-to 5-fold higher risk of developing VTE. The influence of the FII:G20210A mutation on arterial thromboembolic disease is not clear, but there is evidence that it is associated with cerebrovascular ischemic disease (5 ) and myocardial infarction (6 ) .
In addition to these two established thrombotic risk factors, the role of other genetic variations is still under investigation. The A223V (C677T) mutation in the thermolabile methylenetetrahydrofolate reductase (MTHFR) gene is associated with mild hyperhomocysteinemia. Homozygosity for the mutation may be associated with an increased risk for cardiovascular events. The effect of the mutation on venous thrombosis is still controversial (7) (8) (9) (10) .
For diagnostic analyses and for scientific studies of large numbers of patients, fast and economic assays that can be performed with standard PCR instruments are highly desirable.
We developed a mutagenically separated (MS) multiplex PCR for the simultaneous detection of mutations in the FV, FII, and MTHFR genes (11 ) . Our MS-PCR is a single-tube PCR-based technique using allele-specific primers that differ in length by 8 -10 bp. Base mismatches Clinical Chemistry 47, No. 2, 2001 
